Alternatives to Felbamate If You Can't Fill Your Prescription

Felbamate occupies a unique niche in epilepsy treatment: it is only used when other antiepileptic drugs have failed to control seizures and when the benefit of seizure control outweighs the serious risks the drug carries. Because of its very restricted use, there is never a quick substitute—switching medications requires careful medical supervision. That said, there are several FDA-approved alternatives for both of felbamate's primary indications (partial seizures and Lennox-Gastaut syndrome), and your neurologist may have already considered some of them for you.

Important: Never switch, reduce, or stop felbamate on your own. Any transition to an alternative must be managed by your neurologist. Abrupt discontinuation of felbamate can trigger dangerous rebound seizures. This article is for informational purposes—use it to have a more informed conversation with your medical team.

Why Felbamate Alternatives Are a Complex Conversation

Felbamate is specifically approved as a last-resort treatment. Most patients taking it have already tried multiple other antiepileptic drugs that didn't work well enough or caused intolerable side effects. This means the "alternatives" listed below are often drugs you may have tried before, or your neurologist may have already considered and ruled out for your specific situation.

That said, if you truly cannot access felbamate and are facing a gap in supply, having this information on hand will help you advocate for yourself during an urgent medical consultation.

Alternatives for Partial (Focal) Seizures

Felbamate is FDA-approved for adults and adolescents ≥14 years with partial seizures, with or without secondary generalization, when other therapies have failed. The following alternatives are also approved for partial/focal seizures:

Cenobamate (Xcopri)

Cenobamate is a relatively new antiepileptic drug (FDA-approved 2019) for focal-onset seizures in adults. It has a dual mechanism—blocking sodium channels and enhancing GABA-A activity—and has shown impressive seizure reduction rates in clinical trials, including seizure freedom in some patients with drug-resistant epilepsy. It does not carry the same hematologic or hepatic black box warnings as felbamate, making it a compelling option for refractory partial seizures. It is not approved for Lennox-Gastaut syndrome.

Lacosamide (Vimpat)

Lacosamide is FDA-approved for focal-onset seizures in patients 4 years and older. It works by enhancing the slow inactivation of sodium channels, a different mechanism from most other antiepileptics. It has a generally favorable tolerability profile, fewer drug interactions than felbamate, and is available as tablets, oral solution, and IV formulation. It is widely stocked at most pharmacies and is a reasonable option for patients who primarily have focal seizures.

Alternatives for Lennox-Gastaut Syndrome (LGS)

Felbamate is one of eight antiepileptic drugs specifically approved by the FDA for LGS. The others are generally considered safer and are typically tried before felbamate. If you are on felbamate for LGS and face a supply problem, your neurologist may consider the following:

Lamotrigine (Lamictal)

Lamotrigine is FDA-approved for LGS (age ≥2) and partial seizures. It is one of the most commonly used broad-spectrum antiepileptics. Titration must be very slow—going too fast increases the risk of a serious rash (Stevens-Johnson syndrome). It has no hematologic or hepatic black box warnings. Lamotrigine is widely available at almost every pharmacy.

Rufinamide (Banzel)

Rufinamide is FDA-approved as adjunctive therapy for LGS in patients 1 year and older. It is particularly effective at reducing drop attacks (atonic seizures), which are among the most dangerous seizure types in LGS. It is generally well-tolerated, with somnolence and vomiting as the most common side effects. Unlike felbamate, it does not carry life-threatening hematologic or hepatic risks.

Cannabidiol (Epidiolex)

Epidiolex is a plant-derived, pharmaceutical-grade cannabidiol (CBD) approved by the FDA for LGS (age ≥1), Dravet syndrome, and tuberous sclerosis complex. It is one of the newer approved LGS medications and has good clinical trial evidence. It can elevate liver enzymes—especially when combined with valproate—so liver function monitoring is needed. It is non-intoxicating and does not have the same black box profile as felbamate.

Clobazam (Onfi)

Clobazam is a benzodiazepine (Schedule IV) approved for adjunctive treatment of LGS in patients age ≥2. It works by enhancing GABA-A receptor activity. It is effective at reducing seizures but carries risks of sedation, cognitive effects, and physical dependence with long-term use. It may be appropriate as part of a bridging strategy if felbamate supply is temporarily unavailable.

What About Valproate?

Valproate (Depakote) is the preferred first-line treatment for LGS according to expert consensus. It is a broad-spectrum antiepileptic effective against multiple seizure types. It carries its own black box warnings for hepatotoxicity (especially in children under 2), pancreatitis, and fetal risk in pregnancy. Most patients on felbamate will have already tried valproate, but it may be part of an individualized bridging plan.

The Bottom Line: Don't Switch Without Your Neurologist

Alternatives to felbamate exist, but transitioning to them requires careful medical management. If your immediate problem is simply locating felbamate, see our guide on how to find felbamate in stock near you—medfinder can contact pharmacies near you to check availability, saving you hours of phone calls.